mGluR3 (Metabotropic Glutamate Receptor 3), encoded by the GRM3 gene (also known as GRM3 or mGlu3), is a member of the Group II metabotropic glutamate receptor family. Unlike its close relative mGluR2, mGluR3 is predominantly expressed on glial cells—particularly astrocytes and microglia—rather than neurons. This unique cellular distribution positions mGluR3 as a critical regulator of neuroinflammation, glutamate homeostasis, and neuron-glia communication .
The receptor has attracted significant interest as a therapeutic target due to its roles in modulating inflammatory responses, regulating synaptic plasticity through glial mechanisms, and influencing neuronal survival pathways. GRM3 polymorphisms have been linked to schizophrenia, cognitive function, and susceptibility to neurodegenerative diseases, highlighting its importance in human health and disease .
¶ Gene and Protein Structure
The GRM3 gene (Gene ID: 2912) is located on chromosome 7q21.1-q21.2 in humans. The gene spans approximately 30 kb and contains 11 exons. Alternative splicing generates multiple mRNA variants with distinct expression patterns and functional properties. The GRM3 promoter contains regulatory elements that respond to neuronal activity, cytokines, and pathological conditions.
Key structural features:
- Multiple transcription start sites
- Tissue-specific splicing
- Activity-dependent expression regulation
mGluR3 shares the class C GPCR architecture with mGluR2:
| Domain |
Description |
| N-terminal VFT domain |
Large extracellular domain (~400 aa) with ligand binding site |
| Cysteine-rich domain (CRD) |
Flexible linker with structural disulfide bonds |
| 7 Transmembrane domain |
Classic seven-helix bundle |
| C-terminal tail |
Contains serine/threonine phosphorylation sites |
The ligand binding pocket shows high affinity for glutamate, with binding kinetics that differ slightly from mGluR2. The receptor can form both homodimers and heterodimers with mGluR2, creating functionally distinct complexes.
- N-linked glycosylation in the extracellular domains
- Disulfide bonds in the CRD for structural stability
- Phosphorylation at multiple serine/threonine residues
- Palmitoylation for membrane association
mGluR3 can form:
- Homodimers: Functional receptor units
- Heterodimers with mGluR2: Altered pharmacology and signaling
- Complexes with other proteins: Scaffold proteins, glutamate transporters
mGluR3 exhibits distinctive cellular distribution:
- Highly expressed in cortical and hippocampal astrocytes
- Modulates astrocytic glutamate uptake
- Regulates astrocytic metabolic support of neurons
- Influences astrocyte-neuron lactate shuttle
- Expressed on surveillant and activated microglia
- Modulates microglial cytokine production
- Regulates phagocytic activity
- Influences neuroinflammation resolution
- Present on oligodendrocyte precursor cells (OPCs)
- Modulates OPC migration and differentiation
- Affects myelination processes
mGluR3 plays a crucial role in maintaining glutamate balance:
- Astrocytic glutamate uptake: mGluR3 activation enhances glutamate transporter expression (GLT-1/EAAT2)
- Release modulation: Regulates glial glutamate release through system Xc- cystine/glutamate antiporter
- Metabolic coupling: Links neuronal activity to astrocytic metabolic support
mGluR3 is a key modulator of inflammatory responses:
- Pro-inflammatory cytokine reduction: mGluR3 activation decreases IL-1β, TNF-α, IL-6
- Anti-inflammatory phenotype promotion: Shifts microglia toward M2-like state
- Resolution of inflammation: Enhances production of anti-inflammatory mediators
Although primarily glial, mGluR3 influences synaptic plasticity indirectly:
- Modulates astrocytic D-serine release: Affects NMDA receptor activation
- Regulates glutamate clearance: Shapes synaptic glutamate transients
- Influences synaptic scaling: Participates in homeostatic plasticity mechanisms
mGluR3 dysregulation contributes to AD pathogenesis:
- Increased mGluR3 expression in AD brain
- Modulates microglial activation around plaques
- Influences cytokine profile in AD microenvironment
¶ Glutamate Handling
- Reduced astrocytic glutamate uptake in AD
- mGluR3 dysfunction may contribute to excitotoxicity
- Altered astrocytic-neuronal metabolic coupling
mGluR3 modulation offers several therapeutic strategies:
- Agonists could reduce neuroinflammation
- Enhancement of glutamate clearance
- Promotion of anti-inflammatory microglial phenotype
mGluR3 plays important roles in PD:
- Modulates microglial activation in substantia nigra
- Influences dopaminergic neuron survival
- Regulates peripheral immune cell infiltration
- Astrocytic mGluR3 supports neuronal metabolism
- Modulates neurotrophic factor release
- Influences alpha-synuclein clearance mechanisms
GRM3 is a well-established schizophrenia susceptibility gene:
- Genetic variants affect risk
- Altered glutamate signaling contributes to cognitive deficits
- mGluR3 modulators have been explored as therapeutic agents
mGluR3 involvement in ALS:
- Dysregulated glutamate handling in ALS
- mGluR3 modulation may reduce excitotoxicity
- Glial therapeutic targets are attractive for ALS
mGluR3 affects oligodendrocyte function:
- OPC migration and differentiation
- Myelin maintenance
- Remyelination processes
| Compound |
Mechanism |
Status |
Application |
| LY354740 |
mGluR2/3 agonist |
Clinical trials |
Schizophrenia |
| LY379268 |
mGluR2/3 agonist |
Research |
Neuroinflammation |
| DCG-IV |
mGluR2/3 agonist |
Research |
Experimental |
PAMs that enhance mGluR3 function:
| Compound |
Selectivity |
Development |
| VU06507876 |
mGluR3 PAM |
Preclinical |
| AV-101 |
mGluR3 PAM |
Clinical trials |
NAMs have been explored for different indications:
- Potential for cognitive enhancement in certain contexts
- May have pro-inflammatory effects that require caution
- Cell-type specificity: Targeting glial vs. neuronal mGluR3
- Dose-response: Optimal dosing for anti-inflammatory effects
- BBB penetration: Critical for CNS indications
- Combination approaches: Synergy with other therapeutic strategies
mGluR3 couples primarily to Gi/o proteins:
- Adenylate cyclase inhibition → reduced cAMP
- MAPK pathway modulation → ERK1/2 effects
- PI3K/Akt pathway → cell survival signaling
- Calcium signaling through indirect mechanisms
- Beta-arrestin pathways for biased signaling
| Pathway |
Primary Effect |
Cellular Outcome |
| cAMP/PKA |
Reduced signaling |
Decreased excitability |
| ERK/MAPK |
Variable |
Context-dependent |
| PI3K/Akt |
Enhanced survival |
Neuroprotection |
| NF-κB |
Inhibited |
Anti-inflammatory |